Sensorion reported results from the Phase 2 AUDIBLE-S study of SENS-401 (Arazasetron) for the treatment of sudden sensorineural hearing loss (SSNHL). Although SENS-401 was safe…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.